Maltoheptaose-Presenting Nanoscale Glycoliposomes for the Delivery of Rifampicin to E. coli
Source abstract
Abstract
Liposomes, a nanoscale drug delivery system, are well known for their ability to improve pharmacokinetics and reduce drug toxicity. In this work, maltoheptaose (G7)-presenting glycoliposomes were synthesized and evaluated in the delivery of the antibiotic rifampicin. Two types of liposomes were prepared: nonfluid liposomes from l-α-phosphatidylcholine (PC) and cholesterol, and fluid liposomes from 1,2-dipalmitoyl-sn-glycero-3-phosphocholine and 1,2-dimyristoyl-sn-glycero-3-phospho-(1′-rac-glycerol). G7-derivatized glycolipid, G7-DPPE (DPPE: 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine), was incorporated into the liposomes at 21 and 14 μmol/mg to form nanoparticles of 75 ± 12 and 146 ± 14 nm for the nonfluid and fluid G7-glycoliposomes, respectively. The multivalent G7-glycoliposomes were characterized by lectin binding with concanavalin A (Con A). The dissociation constant Kd between Con A and the nonfluid or fluid G7-glycoliposomes was 0.93 or 0.51 μM, which represented ∼900- or 1600-fold stronger affinity than the binding between Con A and G7. The G7-glycoliposomes were loaded with rifampicin at 6.6 and 16 wt % encapsulation for the nonfluid and fluid G7-glycoliposomes, respectively. Introducing a carbohydrate in the liposomes slowed down the release of rifampicin, with the G7-glycoliposomes having the slowest release rate and the lowest permeability coefficient among the liposome formulations. The fluid G7-glycoliposomes lowered the minimal inhibitory concentration (MIC) of rifampicin against E. coli ORN208 by about 3 times, whereas liposomes without G7 or Man (d-mannose)-glycoliposomes showed no improvement in MIC. The rifampicin-loaded fluid G7-glycoliposomes demonstrated the best sustained antibacterial activity against E. coli, with up to 2 log reduction in the colony forming units at 4 × MIC after 24 h. Fluorescence resonance energy transfer and confocal fluorescence microscopy revealed stronger interactions of the bacterium with the fluid G7-glycoliposomes than other liposome formulations.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Lipid Membrane Structure and Behavior · Nanoparticle-Based Drug Delivery · RNA Interference and Gene Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Chemistry, The University of Massachusetts Lowell, Lowell, Massachusetts 01854, United States
Funding
NIH
References (68)
Show source-provided references
1. 10.1038/s41573-020-0090-810.1038/s41573-020-0090-8 ↗
2. 10.12688/f1000research.7595.110.12688/f1000research.7595.1 ↗
3. 10.3390/molecules2107083610.3390/molecules21070836 ↗
4. 10.1208/s12248-015-9780-210.1208/s12248-015-9780-2 ↗
5. 10.1002/btm2.1000310.1002/btm2.10003 ↗
6. 10.1007/s11095-016-1958-510.1007/s11095-016-1958-5 ↗
7. 10.1093/jac/41.1.3510.1093/jac/41.1.35 ↗
8. 10.1016/S0005-2736(99)00217-510.1016/S0005-2736(99)00217-5 ↗
9. 10.1016/j.ijpharm.2008.09.04310.1016/j.ijpharm.2008.09.043 ↗
10. 10.2147/IJN.S4261710.2147/IJN.S42617 ↗
11. 10.2147/IJN.S5580710.2147/IJN.S55807 ↗
12. 10.1016/j.ijpharm.2006.08.03410.1016/j.ijpharm.2006.08.034 ↗
13. 10.1016/S0924-8579(99)00121-110.1016/S0924-8579(99)00121-1 ↗
14. 10.1016/j.tibtech.2013.09.00710.1016/j.tibtech.2013.09.007 ↗
15. 10.1016/j.addr.2012.09.03710.1016/j.addr.2012.09.037 ↗
16. 10.1021/ar00056a00110.1021/ar00056a001 ↗
17. 10.1126/science.143980810.1126/science.1439808 ↗
18. 10.1126/science.109482310.1126/science.1094823 ↗
19. 10.1016/j.ejpb.2015.02.00810.1016/j.ejpb.2015.02.008 ↗
20. Weingart, J. J.; Vabbilisetty, P.; Sun, X.L. Glyco-Functionalized Liposomes; John Wiley & Sons, Inc., 2016; pp 211–232.10.1002/9781118860212.ch8 ↗
21. 10.1002/chem.20150284210.1002/chem.201502842 ↗
22. 10.1039/C5CC04251H10.1039/C5CC04251H ↗
23. 10.1002/adhm.20160007110.1002/adhm.201600071 ↗
24. 10.1002/adhm.20150049110.1002/adhm.201500491 ↗
25. 10.1021/acsbiomaterials.5b0027410.1021/acsbiomaterials.5b00274 ↗
26. 10.1038/nmat307410.1038/nmat3074 ↗
27. 10.1039/c3cc40491a10.1039/c3cc40491a ↗
28. 10.1093/clinids/5.Supplement_3.S40710.1093/clinids/5.Supplement_3.S407 ↗
29. 10.1073/pnas.61.2.66710.1073/pnas.61.2.667 ↗
30. 10.1093/jac/42.5.59710.1093/jac/42.5.597 ↗
31. 10.1016/0022-2836(88)90517-710.1016/0022-2836(88)90517-7 ↗
32. 10.1191/09603270067423083010.1191/096032700674230830 ↗
33. 10.1016/j.ejphar.2007.05.05910.1016/j.ejphar.2007.05.059 ↗
34. 10.1002/jps.2144110.1002/jps.21441 ↗
35. Salem I. I. · Methods Enzymol. · 2005 · 391 · 26110.1016/S0076-6879(05)91015-X ↗
36. 10.1016/j.ijpharm.2018.07.01110.1016/j.ijpharm.2018.07.011 ↗
37. 10.1021/ac102781u10.1021/ac102781u ↗
38. 10.1016/j.bios.2012.01.00110.1016/j.bios.2012.01.001 ↗
39. 10.1351/pac-con-12-08-1310.1351/pac-con-12-08-13 ↗
40. 10.1016/j.carres.2017.09.01510.1016/j.carres.2017.09.015 ↗
41. 10.3390/molecules2401015710.3390/molecules24010157 ↗
42. 10.1016/S0008-6215(97)00187-010.1016/S0008-6215(97)00187-0 ↗
43. 10.1039/c1ob05040k10.1039/c1ob05040k ↗
44. 10.1007/s13346-015-0220-810.1007/s13346-015-0220-8 ↗
45. 10.3109/0898210090334792310.3109/08982100903347923 ↗
46. 10.1016/0005-2736(73)90408-210.1016/0005-2736(73)90408-2 ↗
47. 10.3390/pharmaceutics404059010.3390/pharmaceutics4040590 ↗
48. 10.1364/OE.22.02930410.1364/OE.22.029304 ↗
49. 10.1021/js950474+10.1021/js950474+ ↗
50. 10.1007/s00232990042210.1007/s002329900422 ↗
51. 10.1039/b917900c10.1039/b917900c ↗
52. 10.1126/science.107.2775.25410.1126/science.107.2775.254 ↗
53. 10.1021/ja01340a04810.1021/ja01340a048 ↗
54. 10.1021/ja01182a02510.1021/ja01182a025 ↗
55. 10.1021/bi00650a02610.1021/bi00650a026 ↗
56. 10.1107/S090744499500874210.1107/S0907444995008742 ↗
57. 10.1021/ac102114z10.1021/ac102114z ↗
58. 10.1039/c0cc05299j10.1039/c0cc05299j ↗
59. 10.1016/j.carres.2014.09.00610.1016/j.carres.2014.09.006 ↗
60. 10.1039/c1an15469a10.1039/c1an15469a ↗
61. 10.1039/D0CC05899H10.1039/D0CC05899H ↗
62. 10.2198/sbk.26.17310.2198/sbk.26.173 ↗
63. 10.1128/JB.183.13.4099-4102.200110.1128/JB.183.13.4099-4102.2001 ↗
64. 10.1073/pnas.150974311210.1073/pnas.1509743112 ↗
65. 10.1021/bi00517a02310.1021/bi00517a023 ↗
66. 10.1039/C0CS00115E10.1039/C0CS00115E ↗
67. 10.1039/b917900c10.1039/b917900c ↗
68. 10.1016/j.btre.2015.08.00310.1016/j.btre.2015.08.003 ↗